Effect of intravitreal conbercept injection on VEGF-A and -B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy.
Effect of intravitreal conbercept injection on VEGF-A and -B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy.
复制标题
DOI：
10.3892/etm.2021.9763
复制
发表时间：
2021-04
影响因子：
2.7
通讯作者：
Gao X
中科院分区：
文献类型：
--
作者：
Zhang Y;Gao Z;Zhang X;Yuan Z;Ma T;Li G;Gao X
本研究旨在探讨眼科手术前应用抗血管内皮生长因子治疗以减少术中出血的机制。30例临床诊断为增殖性玻璃体视网膜病变的患者作为手术组。此外，30例患者接受了玻璃体内注射抗血管内皮生长因子药物康贝赛特，并被认为是药物预处理组。手术组患者在玻璃体切除手术中取出眼部房水和玻璃体体液。药物预处理组患者在康贝塞特治疗前和康贝赛特治疗后7天取房水，术后即刻手术。这组人的玻璃体幽默只在手术期间拍摄。用双抗体夹心ELISA法检测房水和玻璃体体液中血管内皮生长因子-A和-B的含量。免疫组织化学染色半定量检测纤维血管增殖膜中血管内皮生长因子A和B的表达。结果表明，药物组患者注射康贝赛特前后房水中血管内皮生长因子-A水平分别为197.66±48.00pg/ml和3.39±2.54pg/ml。手术组和药物组注射后玻璃体液中血管内皮生长因子-A水平分别为267.53±179.60和21.43±5.81pg/ml。康贝赛特治疗前后房水中VEGF-B水平分别为13.66±3.30(注射前)和2.17±0.94pg/ml(注射后)。手术组和药物组玻璃体液中血管内皮生长因子-B水平注射后分别为127.36±16.72pg/ml和18.56±9.82pg/ml(P<0.05)。此外，药物组的手术时间、出血量和毛细血管形成较手术组明显减少。综上所述，康贝赛特治疗后PDR患者房水中VEGF-A和-B水平显著降低。此外，药物组患者玻璃体液中的血管内皮生长因子-A和-B水平较手术组显著下降。这些结果为康贝赛特在PDR患者的术前应用提供了理论依据。
The present study aimed to investigate the mechanisms of anti-VEGF treatment prior to eye surgery to reduce intraoperative bleeding. A total of 30 patients with proliferative vitreoretinopathy after clinical diagnosis were enrolled in the present study as the surgical group. Furthermore, 30 patients underwent intravitreal injection of the anti-VEGF drug conbercept and were considered the drug pretreatment group. The aqueous and vitreous humors from the eyes of patients in the surgical group were drawn during pars plana vitrectomy surgery. The aqueous humor in the eyes of patients in the drug pretreatment group was drawn prior to conbercept treatment and seven days after conbercept treatment immediately prior to surgery. The vitreous humor in this group was only taken during surgery. Furthermore, ELISA was used to detect the levels of VEGF-A and -B in the aqueous and vitreous humors. Semi-quantitative determination of VEGF-A and VEGF-B levels in fibrovascular proliferative membranes was performed using immunohistochemical staining. The results indicated that in the drug group, the levels of VEGF-A in the aqueous humor of patients prior to and after conbercept injection were 197.66±48.00 and 3.39±2.54 pg/ml, respectively. The levels of VEGF-A in the vitreous humor of patients in the surgical and drug groups were 267.53±179.60 and 21.43±5.81 pg/ml after injection, respectively. The levels of VEGF-B in the aqueous humor of patients prior to and after conbercept injection were 13.66±3.30 (before injection) and 2.17±0.94 pg/ml (after injection), respectively. The levels of VEGF-B in the vitreous humor of patients in the surgical and drug groups were 127.36±16.72 and 18.56±9.82 pg/ml after injection, respectively (P<0.05). Furthermore, in the drug group, the surgery time, bleeding and capillary formation were significantly reduced compared with those in the surgical group. Taken together, these results suggested that the levels of VEGF-A and -B decreased significantly in the aqueous humor of patients with PDR after conbercept injection. Furthermore, the levels of VEGF-A and -B in the vitreous humor of patients dropped significantly in the drug group compared with those in the surgical group. These results provide theoretical clinical support for the preoperative application of conbercept for patients with PDR.
登录
查看更多内容
影响因子：
2
作者：
Takahashi, Satoru
通讯作者：
Takahashi, Satoru
影响因子：
13.7
作者：
Hershberger, VS;Augsburger, JJ;Krug, S
通讯作者：
Krug, S
影响因子：
4.2
作者：
Yang, Chung-May;Yeh, Po-Ting;Chen, Muh-Shy
通讯作者：
Chen, Muh-Shy
影响因子：
13.7
作者：
Ahn, Jeeyun;Woo, Se Joon;Park, Kyu Hyung
通讯作者：
Park, Kyu Hyung
影响因子：
1.6
作者：
Dong F;Yu C;Ding H;Shen L;Lou D
通讯作者：
Lou D